Search
Brentuximab vedotin
go.drugbank.com/drugs/DB08870ApprovedInvestigationalThis demonstrates meaningful progress in treatment for patients affected by this disease.[L1739] … [L1737] Adcetris has also been previously approved by the FDA to treat Hodgkin's lymphoma after relapse, Hodgkin's lymphoma after stem cell transplantation when a patient has a high risk of relapse
Products: POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 50MG/VIAL, Adcetris 50mg, powder for concentrate for solution for infusionBordetella pertussis fimbriae 2/3 antigen
go.drugbank.com/drugs/DB10790ApprovedInvestigationalBordetella pertussis fimbriae 2/3 antigen is a vaccine for the prophylaxis of the disease caused by Bordetella pertussis which is a a Gram-negative coccobacillus that expresses two serologically distinct
Tegafur
go.drugbank.com/drugs/DB09256ApprovedInvestigationalTegafur is usually given in combination with other drugs that enhance the bioavailability of the 5-FU by blocking the enzyme responsible for its degradation, or serves to limit the toxicity of 5-FU by … When converted and bioactivated to 5-FU, the drug mediates an anticancer activity by inhibiting thymidylate synthase (TS) during the pyrimidine pathway involved in DNA synthesis. 5-FU is listed on the
Quaternium-15
go.drugbank.com/drugs/DB14198ApprovedIn 2005, Quaternium-15 was named in the top 15 most frequently positive allergens identified in patch tests by the North American Contact Dermatitis Group (NACDG)[A34326]. … It is an anti-microbial agent by virtue of being a formaldehyde releaser, however this can also cause contact dermatitis, a symptom of an allergic reaction, especially in those with sensitive skin.
Dextropropoxyphene
go.drugbank.com/drugs/DB00647ApprovedIllicitWithdrawnDextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions.
Macimorelin
go.drugbank.com/drugs/DB13074ApprovedMacimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution.
OAV201
go.drugbank.com/drugs/DB17842ExperimentalIt was first developed by Novartis and investigated for the treatment of Rett syndrome, but further investigation in clinical trials was halted.[L46661]
1alpha,24S-Dihydroxyvitamin D2
go.drugbank.com/drugs/DB06117ExperimentalStudies have shown LR-103 has the same potency as calcitriol, but much lower toxicity. … LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol.
Etryptamine
go.drugbank.com/drugs/DB01546ApprovedIllicitWithdrawnαET is a stimulant and hallucinogen, but it is less stimulating and hallucinogenic than alpha-methyltryptamine, a closely related compound. … In the 1960's, alpha-ethyltryptamine (αET), a non hydrazine reversible monoamine oxidase inhibitor, was developed in the United States by the Upjohn chemical company for use as an antidepressant. αET was
Umbralisib
go.drugbank.com/drugs/DB14989ApprovedInvestigationalWithdrawn[A229363] Follicular lymphoma is also treated with rituximab and other chemotherapeutic agents, but may show similar progression. … It was marketed as Ukoniq by TG Therapeutics and has been approved for the treatment of relapsing and refractory marginal cell lymphoma and follicular lymphoma in adults.